Multi-functional antibodies

Details Multi-functional antibodies Multi-functional antibodies

2003-07-22

2010-10-26

Fetterolf, Brandon J (Department: 1642)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

C424S155100, C424S175100, C424S178100

Reexamination Certificate

active

07820787

ABSTRACT:
The present invention provides antibodies comprising an antigen recognition domain that specifically binds to a metal chelate: mutant antibodies comprising a reactive site not present in the wild-type of the antibody, wherein the reactive site is in a position proximate to or within the antigen recognition domain; and methods of using such antibodies to diagnose and treat disease.

REFERENCES:
patent: 4678667 (1987-07-01), Meares et al.
patent: 4722892 (1988-02-01), Meares et al.
patent: 5541287 (1996-07-01), Yau et al.
patent: 5747654 (1998-05-01), Pastan et al.
patent: 5789554 (1998-08-01), Leung et al.
patent: 5837242 (1998-11-01), Holliger et al.
patent: 2002/0006379 (2002-01-01), Hansen et al.
patent: 2003/0124057 (2003-07-01), Griffiths et al.
patent: WO 95/15979 (1995-06-01), None
patent: WO 9966951 (1999-12-01), None
patent: WO 00/74729 (2000-12-01), None
Sharkey et al. (2002 ASCO Annual Meeting abstract, Orlando, Fl., May 18, 2002).
Sigma-Aldrich catalog print, DOTA.
Lovqvist et al. (J. Nucl. Med. 1998; 39: 1776-1777).
Goodwin et al. (Cancer 1997; 80: 2675-2680).
Goldberg et al. (Cancer Immunol. Immunother. 2003; 52: 281-296).
Zhu et al (J. Nucl. Med. 1998; 39: 65-76).
Paul, Fundamental Immunology, (textbook), 1993, pp. 292-295.
Rudikoff et al. (Proc. Natl Acad. Sci. USA 1982; 79: 1979).
Chmura et al. (PNAS 2001; 98: 8480-8484).
Goodwin, David A. et al.; “Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: A model for90Y radioimmunotherapy”,Cancer Research; Nov. 15, 1994; pp. 5937-5946; vol. 54.
Karacay, H. et al.; “Pretargeting for cancer radioimmunotherapy with bispecific antibodies: Role of the bispecific antibody's valency for the tumor target antigen”;Bioconjugate Chem.: 2002; pp. 1054-1070; vol. 13; USA.
Lubic, Stephen P. et al.; “Biodistribution and dosimetry of pretargeted monoclonal antibody 2D12.5 and Y-Janus-DOTA in BALB/c mice with KHJJ mouse adenocarcinoma”;The Journal of Nuclear Medicine; Apr. 2001; pp. 670-678; vol. 42., No. 4.
Stickney, Dwight R. et al.; “Bifunctional antibody: A binary radiopharmaceutical delivery system for imaging colorectal carcinoma”;Cancer Research; Dec. 15, 1991; pp. 6650-6655; vol. 51.
Waldherr, Christian et al.; “Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC”;The Journal of Nuclear Medicine; May 2002; pp. 610-616; vol. 43, No. 5.
M. Chinol, et al., “Biodistrubution in tumour-bearing mice of two90Y-labeled biotins using three-step tumour targeting,”Nuclear Medicine Comm., 18:176-182, (1997).
David A. Goodwin, et al., “Pre-targeted immunoscintigraphy: murine tumors with indium-111-labeled bifunctional haptens,”J. Nucl. Med., 29:226-234, (1998).
David A. Goodwin, et al, “Pretargeted Immunoscintigraphy: Effect of hapten valency on murine tumor uptake,” ,J. Nucl. Med., 33:2006-20013, (1992).
D.J. Hnatowich, et al., “Investigation of avidin and biotin for imaging applications,”J. Nucl. Med., 28:1294-1302, (1987).
H.P. Kalofonos, et al. “Imaging of tumors in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies: Preliminary communication,”J. Nucl. Med., 31:1979-1976, (1990).
Alexander L. Klibanov, et al., “Blood clearance of radiolabeled antibodies: Enhancement by lactosamination and treatment with biotin-avidin or anti-mouse IgG antibodies,”J. Nucl. Med., 29:1951-1956, (1988).
J. Ian Marsh, et al., “Streptavidin and biotin as potential tumor imaging agents,”J. Nucl. Med., 29(05):728-729, (1988).
Damon L. Meyer, et al., “Kinectics of the dissociation of Indium-(p-substituted-benzyl)ethylenediaminetetraacetic acid hapten analogues from the monoclonal anti-hapten antibody CHA255,”Bioconiugate Chem., 1:279-284. (1990).
Orlandi et al.,Proc. Natl. Acad. Sci., USA 86:3833-3837. (1989).
Jeffrey T. Owens, et al. “Mapping the promoter DNA sites proximal to conserved regions ofa70in anescherichia coliRNA polymerase-lacUV5 open promoter complex,”Biochemistry, 37:7670-7675, (1998).
Jeffrey T. Owens, et al. “Mapping thea70subunit contact sites onescherichia coliRNA polymerase with aa70conjugated chemical protease,”Proc. Natl. Acad. Sci. USA, 95:6021-6026, (1998).
G. Paganelli, et al., “Three-step monoclonal antibody tumor targeting in carcinoembyonic antigen-positive patients,”Cancer Research, 51:5980-5966, (1991).
G. Paganelli, et al., “Monoclonal antibody pretargeting techniques for tumor localization: the avidin-biotin system,”Nuclear Medicine Comm., 12:211-234, (1991).
Paul et al.,Fundamental Immunology Raven Press. NY, Chapter 8: 242, (1993).
Dayton T. Reardan, et al., “Antibodies against metal chelates,”Nature, 316:265-268, (1985).
Bruno Robert, et al., “Cytokine targeting in tumors using a bispecific antibody directed against carinoembryonic antigen and tumor necrosis factora1,”Cancer Research, 56:4758-4765, (1996).
Eric Rouvier, et al., “Targeting medullary thyroid carcinomas with bispecific antibodies and bivalent haptens ”Horm, Res., 47:163-167. (1997).
Rudikoff, et al.Proc. Natl. Sci. USA, 79:1979-1983, (1982).
B. Schechter, et al., “Indirect immunotargeting of CIS-PT to human epidermiod carcinoma KB using the avidin-biotin system,”Int, J. Cancer, 48:167-172, (1991).
Vladimir V. Sinitsyn, et al., “Rapid blood clearance of biotinylated IgG after Infusion of avidin,”J. Nucl. Med., 30:66-69, (1989).
Fan Yuna, et al., “Pharmacokinetic analysis of two step approaches using bifunctional and enzyme-conjugated antibodies,”Cancer Research, 51:3119-3130, (1991).

Affiliated with

Also associated with

Rating

Multi-functional antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Multi-functional antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multi-functional antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4181113